PCP
SUPN icon

Perbak Capital Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Perbak Capital Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,754
Closed -$349K – 223
2026
Q1 		$349K Buy
+6,754
New +$344K 0.09% 246

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Perbak Capital Partners's SUPN Position: Q2 2026 in Review

Perbak Capital Partners sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 6,754 shares — an estimated $349K sold.

Perbak Capital Partners first reported a position in SUPN in Q1 2026 and held it in 1 quarter. The position peaked at $349K in Q1 2026. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Perbak Capital Partners reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Perbak Capital Partners sold 6,754 Supernus Pharmaceuticals shares in Q2 2026, an estimated $349K.
  • Perbak Capital Partners first reported a position in Supernus Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Perbak Capital Partners's Supernus Pharmaceuticals position peaked at $349K in Q1 2026.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.